U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Medtronic Neuromodulation - 11/02/2017
  1. Warning Letters


Medtronic Neuromodulation

Medtronic Neuromodulation

United States

Issuing Office:

United States



Black HHS-Blue FDA Logo


Minneapolis District
250 Marquette Avenue, Suite 600
Minneapolis, MN 55401
(612) 758-7133 


November 02, 2017

Omar S. Ishrak
Chief Executive Officer
Medtronic, Inc.
710 Medtronic Parkway
Minneapolis, Minnesota 55432

Dear Mr. Ishrak:

The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter MIN 12-39. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.


Timothy G. Philips
Compliance Officer
Office of Medical Device and Radiological Health Operations (OMDRHO)
Division 2 – Central
Minneapolis District 

Back to Top